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Autism spectrum disorders are neurodevelopmental disorders characterized by
significant deficits in reciprocal social interactions, impaired communication and
restricted, repetitive behaviors. As autism spectrum disorders are among the most
heritable of neuropsychiatric disorders, much of autism research has focused on
the search for genetic variants in protein-coding genes (i.e., the ‘trees’). However,
no single gene can account for more than 1% of the cases of autism spectrum
disorders. Yet, genome-wide association studies have often identified statistically
significant associations of genetic variations in regions of DNA that do not code
for proteins (i.e., intergenic regions). There is increasing evidence that such
noncoding regions are actively transcribed and may participate in the regulation
of genes, including genes on different chromosomes. This article summarizes
evidence that suggests that the research spotlight needs to be expanded to
encompass far-reaching gene-regulatory mechanisms that include a variety of
epigenetic modifications, as well as noncoding RNA (i.e., the ‘forest’). Given that
noncoding RNA represents over 90% of the transcripts in most cells, we may be
observing just the ‘tip of the iceberg’ or the ‘edge of the forest’ in the genomic
landscape of autism.

Autism spectrum disorders (ASDs) refer
collectively to a group of neurodevelopmental
disorders diagnosed on the basis of abnormal
development and behaviors, which include
social and communication deficits, as well
as the manifestation of restricted interests
and stereotyped repetitive behaviors [1]. The
phenotypes of ASDs range from a total lack of
language and social isolation characteristic of
the most severe form (classic autism) described
by Kanner [2], through to a more moderate
phenotype known as pervasive developmental
disorder – not otherwise specified, to the
mildest variant, known as Asperger’s syndrome,
which is typically not associated with clinically
significant language and cognitive deficits [3].
As ASDs are among the most heritable of all
psychiatric disorders, much effort has been
placed on understanding the genetics of autism,
specifically identifying genetic variants and other
chromosomal abnormalities that are responsible
for the etiology of autism [4,5]. However, unlike
the genes that are causal for syndromic disorders
(such as fragile X syndrome) that sometimes
manifest with autistic symptoms (recently
reviewed by Benvenuto et al. [6]), no single gene
can be considered ‘causal’ for more than 1% of
the cases of idiopathic autism. This observation
may relate to the phenotypic heterogeneity of
10.2217/FNL.12.83 © 2013 Future Medicine Ltd

ASDs. In this article, I emphasize the need to
look beyond the search for structural variants in
protein-coding genes (the ‘trees’) to investigate
a variety of gene-regulatory mechanisms (the
‘forest’) that may disrupt the expression of large
batteries of genes responsible for the pervasive
characteristics of ASDs (Figure 1).
Genetics of ASDs

To date, many different approaches have been
used to investigate the genetics of ASDs, from
gene or chromosome-focused linkage analyses
and family-based association tests to the more
recent genome-wide linkage and association
analyses, which have interrogated hundreds of
thousands of single nucleotide polymorphisms
(SNPs) in thousands of probands and families.
These studies have together resulted in the
identification of hundreds of candidate genes
for ASDs (the latest estimates approaching
400 genes [7]), with relatively few genes replicated
among the different studies and cohorts. A
recent genome-wide association (GWA) study
of common SNPs illustrates the vexing problem
of identifying highly significant and replicable
risk alleles. In this study, most of the SNPs with
a nominal p-value <5 x 10 -6 in the discovery
phase, including one that exhibited genome-wide
significance at p = 2.1 x 10 -8, actually decreased
Future Neurol. (2013) 8(1), 29–42
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Figure 1. The expansive genomic landscape of autism. Much of the effort in
autism research over the past 15 or more years has focused on identifying rare and
exonic single nucleotide polymorphisms in protein-coding genes, with the number
of genes rapidly increasing. This article takes the perspective that there is a vast
genomic landscape yet to be explored in order to gain a better understanding of
the gene regulatory mechanisms that may contribute to the etiology and
pathogenesis of autism.

in significance when independent cohorts (some
exceeding 1000 probands each) were combined
[8], most likely due to the increased phenotypic
heterogeneity in the combined cohort. Increased
LOD scores (i.e., better p-values) were achieved
in a number of genome-wide linkage analyses
in which the affected individuals were stratified
by subphenotypes [9–14]. However, additional
studies using independent cohorts are needed
to replicate the improvements in LOD scores
achieved by subphenotyping efforts, and the
replication studies need to apply the same
criteria for subtyping ASD cases in order to be
comparable to each other. The findings from
a wide range of genetic studies on ASDs have
been extensively covered in a number of excellent
reviews [15–18], and thus will not be discussed
further here.
Recently, five papers reported the results of
whole exome sequencing in which genomic
DNA enriched for exonic sequences (covering
the protein-coding regions of genes) were
subjected to next-generation (next-gen)
sequencing methods, which determine the
30
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base sequences of hundreds of thousands of
oligonucleotide molecules captured on exome
arrays containing probes that are designed to
recognize and hybridize to exonic sequences in
the genome [7,19–23]. The primary goal of such
studies was to identify, in an unbiased manner,
rare and de novo genetic mutations as well as
copy number variants associated with ASDs.
With a few exceptions, there was relatively
little overlap among the genes identified by
these studies. However, 13–14% of the genes
identified in two of the studies [19,20] overlapped
with genes that were differentially expressed in
lymphoblastoid cell lines (LCL) derived from a
subtype of ASD characterized by severe language
impairment [24]. The latter study suggests that
incorporating ASD subphenotypes into genetic
analyses might improve the ability to corroborate
genetic variants among different cohorts. Indeed,
Hu et al. also demonstrated in a meta-analysis
of published GWA data that dividing the cases
into four ASD subphenotypes (subtypes) based
on cluster analyses of functional/behavioral
severity scores from the Autism Diagnostic
Interview – Revised [25], considered a ‘goldstandard’ measure for autism, revealed 18 novel
subtype-associated SNPs, with ten of the SNPs
associated with two or more ASD subtypes
[26]. However, the ten shared SNPs exhibited
distinctly different minor allele frequencies and
odds ratios among the subtypes, indicative of
the genetic differences among these subtypes.
Interestingly, the differences in minor allele
frequencies of these ten shared SNPs between
subtypes were sufficient to obscure any
significant SNP association with ASD when
the four subtypes were combined into one large
case group. More importantly, all 18 SNPs were
found to be in noncoding regions (i.e., promoter,
intronic and intergenic regions), suggesting their
involvement in gene regulation rather than overt
structural aberrations in the associated proteins.
For example, a SNP at the intron boundary of
the serotonin receptor 4 gene (HTR4 ) may
be associated with its expression level, which
was observed in a separate study [24] to be
only reduced in LCL from the ASD subtype
distinguished by severe language impairment;
the odds ratio for the SNP in this subtype was
1.44, but not in LCL from two other ASD
subtypes (moderate and mild) for which the
odds ratios were approximately 0.7. Thus, this
study suggests that using gene expression as
a quantitative trait may be a powerful way of
identifying functionally relevant genetic loci. To
date, there are no published studies on expression
future science group
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quantitative trait loci analyses involving ASDs.
In summary, the abovementioned subphenotypedependent meta-analysis of GWA data, coupled
with the results of recent GWA studies showing
that the most significant SNPs are outside of
exons [8,27,28], suggest that noncoding regions
(which may associate with coding variants
through linkage disequilibrium) and epigenetic
mechanisms of gene regulation should also be
considered in the etiology of autism.
Beyond genetics: epigenetics
& environment

Epigenetics refers to the study of potentially
heritable changes in gene expression and
phenotype that do not involve changes in the
sequence of nucleotides in DNA. The most
studied epigenetic mechanisms include DNA
methylation and histone modifications, which
together determine the availability of a segment
of DNA to transcriptional activators, as well as
microRNA expression, which has been shown to
regulate gene expression at post-transcriptional
levels [29,30]. The relatively recent demonstration
that epigenetic modifications to the genome can
result in transgenerational (inherited) changes
in organismic phenotype, including psychiatric
conditions [31], has intensified the focus on
epigenetic mechanisms operating in complex
neurological disorders [30]. However, epigenetic
studies on ASDs are not trivial because epigenetic
regulation of gene expression is typically
tissue-specific, and the availability of postmortem brain tissues, particularly from wellcharacterized donors with ASDs, is very limited,
thus impeding robust correction for multiple
testing in genome-wide epigenetics analyses. On
the other hand, peripheral tissues or cell lines
derived from well-phenotyped living individuals
may be useful as an experimental surrogate to
identify at least some of the epigenetically
dysregulated genes that may play a role in the
pathobiology of ASDs. In this section, studies
on each of the common epigenetic mechanisms
will be briefly reviewed within the context of
ASD, and the way in which environment may
contribute to epigenetic changes and disease
susceptibility will be discussed.
DNA methylation

DNA methylation involves the attachment of
a methyl group to cytosine(s) in DNA. When
the cytosines occur in a proximal promoter
region enriched in CpG dinucleotides (i.e., CpG
island), methylation typically (but not always)
results in suppression of gene expression. More
future science group
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recently, methylation in other regions of the
genome outside of CpG islands, including gene
bodies and more distal promoter regions, have
been described, with varying consequences on
gene expression [32–35]. The relevance of DNA
methylation to neurodevelopmental disorders
was first recognized in the context of syndromic
disorders, such as fragile X and Rett syndromes,
in which a fraction of individuals also manifest
autism. The etiology of fragile X syndrome
involves the expansion of a CGG trinucleotide
repeat in the 5´ untranslated region of the
FMR1 gene, which is subsequently silenced by
methylation of the CGG expanded promoter
region, resulting in reduced expression of the
protein product, FMRP [36–38]. Unlike the
etiology for much of idiopathic autism, FMRP
deficiency due to mutations in a single gene,
FMR1, is causal for the disorder.
Rett syndrome, on the other hand, is caused
by a mutation in the gene, MECP2, which
recognizes methylated cytosines in DNA [39–42].
Although MeCP2 has been thought to silence
genes by binding to CpG island regions and
preventing transcription, only 6% of MeCP2
binding sites genome wide were found to be in
CpG islands, and surprisingly, 63% of genes
whose promoters were bound to MeCP2 in a
neuronal cell line were actively transcribed rather
than repressed [43]. This study, demonstrating
that the majority of MeCP2 binding sites are
intronic or intergenic, thus provides sufficient
reason to re-examine the function of MeCP2,
as well as DNA methylation in relation to gene
regulation.
With respect to nonsyndromic or idiopathic
autism, expression profiling studies that
reveal differential gene expression between
monozygotic twins discordant for autism
diagnosis and behavioral phenotype are highly
suggestive of the operation of epigenetic factors
in ASDs [44]. To investigate the possibility that
differential methylation might be involved in
idiopathic ASDs, Nguyen et al. used CpG island
arrays to conduct global methylation analyses
of LCL (a surrogate model) derived from
discordant monozygotic twins and sib pairs [45].
The differentially methylated genes were then
compared with differentially expressed genes
that were identified by separate gene expression
analyses of LCL from the same individuals to
identify genes for which increased methylation
was associated with decreased expression and
vice versa [44,46]. Importantly, the expression of
one of the confirmed differentially methylated
genes, RORA, was also found to be reduced
www.futuremedicine.com
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in LCL from a separate cohort of unrelated
ASD-diagnosed individuals with a phenotype
dominated by severe language impairment [24],
as well as in post-mortem brain tissues (frontal
cortex and cerebellum) of two separate cohorts
of affected donors in comparison to unaffected
controls [45,47]. These four separate studies,
showing reduction of RORA in LCL and brain
tissues of individuals with ASDs, demonstrate
that at least some of the molecular changes in
cell lines derived from peripheral tissues are
reflected in the autistic brain. Collectively,
these studies illustrate the value of integrating
data across large-scale genomic analyses
(e.g., identifying differentially expressed
genes that may be dysregulated by aberrant
methylation), as well as the use of peripheral
tissues as surrogate experimental models for a
neurological disorder in an integrative ‘systems’
approach toward understanding the underlying
pathobiology of ASDs, as described in more
detail elsewhere [48,49]. The relevance of RORA
to the pathobiology of autism will be addressed
later in the context of gene–environment
(G × E) interactions.
With respect to the regulation of genes
associated with autism susceptibility by DNA
methylation, Gregory et al. showed that reduced
expression of the OXTR gene was the result of
CpG island methylation in both peripheral
blood mononuclear cells and brain tissues from
individuals with ASD [50]. Interestingly, they
were led to investigate methylation differences
at this gene upon discovery of a copy number
variant in OXTR in an autistic proband that was
not present in his affected sibling, who instead
exhibited enhanced methylation of OXTR.
Thus, both genetic and epigenetic factors were
found to contribute to reduced OXTR expression
in siblings from the same family, and the
methylation status of OXTR in peripheral blood
cells was shown to reflect similar methylation
in brain tissues, again supporting the use of
the blood cells as an experimental surrogate for
brain cells in this case.
Histone modifications & chromatin
remodeling

The packaging of DNA in the nucleus and its
availability for transcription is dictated by the
core histone proteins around which DNA is
wrapped and associated chromatin remodeling
proteins, many of which are involved in posttranslational modifications of histone proteins
[29]. The histone modifications occur on the
protruding histone ‘tails’ (N-termini), which
32
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are accessible on the surface of chromatin
to modifying enzymes, which generally
include histone acetylases, deacetylases and
methyltransferases. These modifications provide
signals for the recruitment of additional proteins
that either activate or repress transcription at a
particular locus.
At present, there is relatively limited
information on the involvement of histone
modifications in ASDs. However, a recent study,
which explored a specific histone modification,
trimethylation of H3K4me3, in neuronal and
non-neuronal cells from the post-mortem
prefrontal cortex of individuals with autism and
controls, demonstrated excess spreading of this
histone modification from the transcriptional
start site of a number of autism-relevant genes in
neurons from approximately 25% of the cases,
with no differences in H3K4me3 modification
noted in controls [51]. Furthermore, this
modification was positively associated with
the activation of the respective gene, thus
demonstrating dysregulation of gene expression
in autism by a specific histone modification. The
fact that only a fraction of the cases exhibited
these changes suggests that this particular form
of epigenetic regulation may apply to a specific
subphenotype of ASD, or a subset of individuals
within a subphenotype.
MicroRNA-dependent gene regulation

Another epigenetic mechanism that has been
studied to a limited extent with respect to ASDs
is microRNA (miRNA) expression. MiRNAs are
endogenous, single-stranded, noncoding RNA
molecules approximately 20–22 nucleotides long
that negatively regulate gene expression posttranscriptionally by inhibition of translation
or by target mRNA degradation [52]. Recently,
miRNAs have also been shown to play a role in
gene activation [53,54], thus broadening the scope
and potential of gene regulation by miRNAs.
The involvement of miRNAs in neurogenesis,
neural differentiation and development is well
documented [55–58], and there is increasing
evidence for miR NA dysregulation in
neurological diseases and psychiatric disorders
[59–61]. To date, four studies have implicated a
role for miRNAs in ASDs. Abu-Elneel et al. first
reported 28 miRNAs that were differentially
expressed in cerebellar tissues from at least one
of 13 autistic individuals relative to a control
set of 13 age-, gender-, post-mortem index- and
hemisphere-matched controls [62]. Talebizadeh
et al. also profiled miRNA expression, but in
LCL from six individuals with ASD and six
future science group
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age- and sex-matched individuals, identifying
nine differentially expressed miRNAs between
cases and controls [63]. Although previously
identified autism candidate genes were among
the predicted targets for the miRNAs identified
in both studies, none of the putative targets were
directly validated in either study. Interestingly,
four out of the nine miRNAs from the latter
study overlapped with those identified by the
former study, suggesting that LCL derived from
peripheral tissues may be useful experimental
models that reflect at least some of the molecular
changes in the autistic brain.
Two subsequent studies coupled miRNA
expression profiling with gene expression
profiling in LCL from the same samples in an
effort to reveal novel targets of miRNAs in ASDs.
In a study of monozygotic twins and sibling pairs
discordant for diagnosis of autism, Sarachana
et al. identified 43 differentially expressed
miRNAs whose expression profiles completely
separated cases from controls [64]. Interestingly,
16 of the miRNAs had been previously reported
to be involved in neural differentiation and
function [65–67]. Putative gene targets ID3
and PLK2 of two real-time quantitative PCRconfirmed brain-specific miRNAs (hsa-miR-29b
and hsa-miR-219–5p), were further validated by
miRNA overexpression and knockdown assays,
respectively. While ID3 is involved in inhibiting
neuronal differentiation and maintaining the
neural stem cell pool [68,69], PLK2 is critical for
neuronal differentiation [70] and homeostatic
synaptic plasticity [71]. In silico functional ana
lysis of all of the predicted gene targets whose
transcripts showed opposite changes from those
of the respective differentially expressed miRNAs
revealed gene networks involved in embryonic
development, synaptic development and function,
circadian rhythm signaling, inflammation,
androgen metabolism and digestive functions,
all of which are relevant to dysregulated processes
in ASDs. Similarly integrating miRNA and
mRNA expression in LCL derived from case–
control siblings, Ghahramani Seno et al. reported
12 miRNAs that were differentially expressed in
at least 12 out of 24 sib-pair comparisons [72].
Although there was some overlap of differentially
expressed miRNAs among the four studies, there
was no consistent pattern of miRNA expression.
It is postulated that this inconsistency is in part
due to the phenotypic heterogeneity of the cases
employed in the different studies. In support
of this hypothesis, significant improvements in
p-values (almost seven orders of magnitude for
miR486–5p) were achieved and seven additional
future science group
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miRNAs were revealed when similarity of mRNA
expression profiles were used to define cohorts
[72]. Thus, this study further demonstrates the
added value of subtyping subjects (in this case
by similar gene-expression profiles) for large-scale
genomic analyses.
G × E interactions

There is increasing evidence that environment
may contribute to risk for ASDs [73–75]. In this
review, the term ‘environment’ broadly refers
to both intrinsic (e.g., hormones) as well as
extrinsic (e.g., pesticides) factors, which are
not part of the genome per se, but can affect
gene expression and phenotype. Environmental
factors frequently impact disease susceptibility
through epigenetic modifications, resulting
in an altered ‘epigenome’. However, little is
known regarding gene-specific epigenetic
modifications or G × E interactions that may
increase risk for ASDs.
The schematic in Figure 2 describes an example
in which the expression of a functionally
relevant candidate gene for ASDs, RORA, is
modulated by both epigenetic modification
and physiological environment (i.e., level of sex
hormones). As mentioned earlier, RORA was
found to be differentially methylated in LCL
from individuals with ASD relative to controls
[45]. Increased methylation was associated with
decreased expression, since treatment of LCL
with a methylation inhibitor increased RORA
expression. Interestingly, RORA was found to
be regulated by male and female hormones but
in opposite directions, with dihydrotestosterone
suppressing and estradiol enhancing RORA
expression [47]. ROR A was also found to
regulate CYP19A1, the gene for the aromatase
enzyme that is responsible for conversion of
testosterone to estradiol. The correlated decrease
in RORA and aromatase protein expression in
the post-mortem frontal cortex further suggests
an inhibitory feedback mechanism in which
reduction of RORA and aromatase proteins
may lead to increased testosterone, which further
suppresses RORA expression [47]. These studies
thus reveal a plausible biological explanation
for the elevated testosterone levels that have
been proposed as a sex-dependent risk factor
for autism, which is strongly biased toward
males [76]. Conversely, higher estrogen levels in
females may lead to increased RORA expression,
which may buffer against RORA deficiency.
Aside from providing a possible mechanistic
explanation for elevated testosterone levels and
sex bias, RORA deficiency can also impact a
www.futuremedicine.com
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Figure 2. A summary of experimental findings that show how both
epigenetic as well as environmental factors (i.e., sex hormones) can
contribute to dysregulation of RORA, a functionally relevant autism
susceptibility gene. DNA methylation decreases expression of RORA in
lymphoblastoid cell lines [45] . Reflecting the decreased expression in lymphoblastoid
cell lines, a decrease in RORA protein is observed in post-mortem brain tissues of
individuals with autism spectrum disorders relative to age-matched unaffected
controls [45,47] , and is correlated with a decrease in aromatase protein in the frontal
cortex. A decrease in aromatase is expected to lead to a build up of its substrate,
testosterone, which we show can further suppress RORA expression through
feedback inhibition by DHT, a potent metabolite of testosterone [47] . Aromatase
deficiency also results in lower estradiol, a positive regulator of RORA expression
[47] , thus further exacerbating RORA deficiency. We do not yet know the original
underlying cause for the increased methylation of RORA in lymphoblastoid cell lines
or for reduced RORA protein in brain tissues.
ASD: Autism spectrum disorder; DHT: Dihydrotestosterone.
Adapted from [47] , provided by Tewarit Sarachana.

number of other physiological functions known
to be impaired in ASDs. Based on studies with
a Rora-deficient mouse model, these functions
include Purkinje cell differentiation and survival
[77,78], cerebellar development [79], protection
against neuroinflammation and oxidative stress
[80,81], regulation of circadian rhythm [82] and
transcriptional regulation of a number of genes
that function at the glutamatergic synapse [83],
thus suggesting that RORA is a functionally
relevant autism susceptibility gene. Interestingly,
the Rora-deficient staggerer mice also exhibit
some behaviors that are characteristic of autism,
including perseverative tendencies and impaired
discrimination learning [84]. Thus, ROR A
deficiency, which has been associated with at
least one subtype of ASD [24], may contribute
to some of the neuropathology and behaviors
observed in individuals with ASDs.
Although we do not yet understand the
factors causing increased methylation of
34
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RORA, the methylation status of the genome
can be influenced by many factors, including
environmental pollutants, drugs and diet,
which are discussed in a comprehensive review
by LaSalle [85]. The demonstrated hormone
sensitivity of ROR A makes it particularly
vulnerable to dysregulation by environmentally
dispersed endocrine-disrupting compounds,
such as bisphenol A (a plasticizer) and atrazine
(an herbicide), which mimic or antagonize
natural hormones, thus interfering with
normal hormonal signaling processes [86,87].
In fact, La Salle and colleagues have recently
demonstrated persistent epigenetic interactions
between exposure to an environmental pollutant
and a mutation in the Mecp2 gene (homologous
Rett syndrome gene) in mice, which resulted
in global hypomethylation of DNA in the
brain of adult female offspring from perinatally
exposed dams [88]. Again, the mechanism for
the altered methylation pattern is not clear.
Recent studies by James and colleagues have
associated genes and metabolites in the folate
and transmethylation metabolic pathways with
global DNA hypomethylation, particularly in
the mothers of children with autism who harbor
a specific risk allele for the reduced folate carrier
gene, RFC1 [89]. These findings emphasize
the impact of the intrauterine environment
as a possible risk factor for ASD, since only
the mothers (and not the affected children)
possess the risk allele, and suggest that dietary
correction of folate or methyl donor deficiency
might lower risk for ASD in children of women
with deficits in folate metabolism [75].
Interplay between genetic & epigenetic
mechanisms

Although epigenetics refers to heritable changes
that do not involve a change in DNA sequence,
there is substantial crosstalk between genetic and
epigenetic mechanisms. For example, mutations
in DNA may alter normal sites of DNA
methylation, and altered methylation patterns or
histone modifications may predispose segments
of DNA to hypermutation. A recent study by Li
et al. reported that ‘methylation deserts’, regions
of lowest methylation comprising approximately
1% of the genome in germline (sperm) cells, are
‘hotspots’ for SNPs and structural mutability
[90] . Furthermore, copy number variants
(i.e., microdeletions and duplications in DNA),
including de novo copy number variants that, as
a group, have been associated with autism [91–93],
are enriched within these methylation-poor
regions [90]. Notably, pseudogenes (a class of
future science group
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noncoding DNA to be discussed later) are also
enriched approximately twofold in methylation
deserts. Thus, the structural mutability
associated with aberrant DNA methylation in
germline cells, which may result from poor
nutrition, exposure to environmental toxins or
other insults affecting methyl donor availability,
may lead to heritable genetic mutations giving
rise to a variety of complex disorders in progeny.
Small noncoding miRNAs are no less
protected from genetic mutation than proteincoding genes. A recent study by Sun et al.
that investigated naturally occurring SNPs in
16 miRNA genes on the X chromosome of males
found 24 point mutations in either the mature
miRNAs or their precursors [94]. Analyses of
these mutated miRNAs revealed that the SNPs
disrupted miRNA processing as well as target
recognition. An additional study by this group,
which focused on miRNA SNPs associated with
schizophrenia, identified eight ultra-rare variants
in the precursor or mature miRNA genes that
resulted in altered expression levels including
gain/loss of function [95]. Thus, the effect of
genetic mutations on miRNA biogenesis and
function adds another layer of complexity to
the interface between genetics and epigenetics
and its impact on disease. Aside from SNPs
in miRNA genes, genetic variation in other
noncoding regions of the genome, for example,
enhancer or repressor binding sites, which may
be kilobases away from gene promoters, may also
associate with altered gene regulation and disease
susceptibility.
The unexplored noncoding ‘dark matter’
in the depths of the genomic ‘forest’

In humans, protein-coding regions of the
genome account for less than 2% of the DNA
in a cell, with the majority of the remaining
approximately 98% of DNA initially considered ‘junk DNA’. Recently, a number of studies
have suggested that approximately 70–90% of
the DNA in human cells is actively transcribed
[96–100]. The term genomic ‘dark matter’ was
first used by Johnson et al. to refer to such
ncRNA transcripts that fall outside of proteincoding genes and which, for the most part, were
of unknown function [101].
However, the idea that ncRNA is indeed an
important and functional contributor to gene
regulation and the developmental complexity
of higher organisms, including humans, was
first advanced by Mattick [102]. His proposal
countered the then-prevailing dogma of genetic
information flow in biological systems from DNA
future science group
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to RNA to proteins, with proteins performing
not only structural and catalytic functions,
but also the majority of regulatory functions
required for the coordinated and properly
timed gene expression in the development of all
organisms. The recent emergence of ncRNA as
multifunctional gene-regulatory molecules thus
requires a reassessment of the role of ncRNA
in development as well as in diseases, especially
phenotypically complex disorders such as ASDs.
Emerging functions of ‘dark matter’
ncRNA

Strictly speaking, the term ncRNA could apply
to any RNA transcript that does not code for
protein, including transfer RNA, ribosomal
RNA, miRNA (discussed above), small nucleolar
RNA, which are involved in RNA splicing and
other RNA modifications, piwi RNA, which
are associated with transposon silencing in
germline cells, and long ncRNA (lncRNA),
which are the most varied and enigmatic of the
ncRNAs [103]. As functions have been identified,
at least broadly, for the first five ncRNA species
mentioned and reviewed elsewhere, this section
will focus on lncRNAs functions of which are
least understood and thus comprise the major
part of ‘dark matter’ RNA [103,104].
lncRNAs (≥200 nucleotides) originate from
intronic as well as intergenic regions and are also
transcribed as antisense transcripts to proteincoding genes. ‘Pseudogenes’, which may have
arisen by faulty or incomplete duplication of a
parental gene or by retrotransposition of a transcribed parental gene from which they are distinguished by the lack of open reading frames
and the presence of poly(A) tails, also contribute
to the lncRNA pool when transcribed. Because
of their sequence similarity to the parent gene,
pseudogene regions are also a rich source of
natural antisense transcripts (NATs) that may
regulate the parental gene. An example of this
phenomenon is the demonstration that a lncRNA
encoding a NAT to the Oct4 pseudogene 5 regulates the transcription of Oct4 in trans (i.e., on a
separate chromosome) as well as the expression
of Oct4 pseudogenes 4 and 5 in cis in mice [105].
Interestingly, when this NAT was suppressed
with small interfering RNAs, expression of the
Oct4 gene increased with the loss of silencing epigenetic marks at the Oct4 promoter. Importantly,
this study reveals the intricate inter-relationships
between gene regulation by lncRNA and epigenetic modifications on histones. In addition, such
epigenetic modifications can have long-lasting
effects on gene expression, lasting 28 days in
www.futuremedicine.com
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one instance involving small dsRNA-induced
transcriptional gene silencing of UbC, which
resulted in early increases in histone methylation
followed later by DNA methylation at the UbC
promoter [106]. Thus, ncRNA may induce epigenetic changes with potential for transgenerational
transmission.
Evidence for involvement of lncRNA
in ASDs

The first association of a lncRNA with
ASDs was the report of a breakpoint in the
chromosomal 7q31.3 region, which contains a
ncRNA transcript (GenBank ID# CB338058)
[107]. Although there was no follow-up study on
this region, it is interesting that this lncRNA
is on the opposite strand just upstream of
the gene KCND2, which has recently been
identified as a candidate gene for ASDs [108]. A
more recent study [109] examined a noncoding
intergenic region 5p14.1 on chromosome 5
containing SNPs, which were reported to be
highly significant in an earlier GWA analysis
[28]. Interestingly, Kerin et al. found that this
region encoded a 3.9 kb ncRNA, which was an
antisense transcript to MSNP1AS and which
can regulate in trans the expression of the MSN
gene on chromosome X in human cell lines
[109]. However, although the antisense ncRNA
is increased in post-mortem brain tissues from
individuals with ASD, there was no difference in
MSN protein levels, which were instead found
to be negatively correlated with the difference
between MSN and MSNP1AS expression levels.
This complex pattern of gene regulation related
to the expression of antisense ncRNA coupled
with the fact that there are many more highly
significant SNPs in noncoding regions that
have been identified in GWA studies of ASDs
suggest that this finding may just be the ‘tip of
the iceberg’ with respect to the involvement of
lncRNA in ASDs [109].
In a genome-wide expression profiling study
of LCL published in 2009, we reported that
20 lncRNAs were the only shared differentially
expressed transcripts (relative to unaffected
controls) among three subgroups of individuals
with ASDs who were subphenotyped according
to cluster analyses of 123 severity scores from the
ADI-R assessment [24,25]. Based on expression
studies reported in the Gene Expression Omnibus
repository, the majority of these transcripts were
found to be expressed in a variety of cell types
and differentially expressed either in androgendependent versus -independent prostate cancer
cell lines or in dihydrotestosterone (DHT)-treated
36
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versus untreated fibroblasts from individuals with
androgen insufficiency syndrome [110,111]. To
investigate the implied involvement of androgen
in the regulation of these transcripts as well as
to examine expression in a neuronal cell model,
we treated SH-SY5Y human neuroblastoma cells
with DHT and found that DHT altered the
expression of all seven of the transcripts analyzed.
Most of the 20 transcripts are intronic and in
antisense orientation to the respective parent genes
[24]. Although we do not yet know the function
of these noncoding transcripts, the expression
of these transcripts in different tissues and their
regulated response to DHT suggest that these
transcripts may have biological function and are
not mere artifacts of faulty transcription. On the
other hand, the fact that all of the transcripts are
decreased in all three subtypes of ASD relative to
unaffected controls may suggest a problem with
splicing, but one that uniformly affects only these
intronic transcripts. In this regard, it is noted
that androgen-responsive intronic transcripts
were reported to associate with alternative
usage of exons or expression levels of the parent
protein-coding genes [112], but we did not detect
differential expression of the parent genes of the
intronic transcripts in our study. Thus, if these
novel lncRNAs regulate gene expression, they
may be acting in trans. Moreover, the androgen
sensitivity of these shared lncRNA transcripts
is intriguing, given the 4:1 bias toward males
in ASDs.
Roles of lncRNA in neurological
development, functions & diseases

Although little is known about the biological
functions of lncRNAs in neural development,
their importance within the CNS is strongly
indicated by the specific expression of 849 out
of 1328 lncRNAs in specific cell types as well as
neuroanatomical and subcellular regions in the
mouse brain [113]. In humans, the involvement
of lncRNAs in CNS development and function
is implicated by dysregulated expression of an
increasing number of noncoding transcripts in
various neuropsychiatric and neurodegenerative
diseases [114,115]. Aside from those that were
described in the preceding section as being
associated with ASDs, two lncRNAs (FMR4
and ASFMR1) that are expressed from the
fragile X mental retardation gene locus
were found to associate with both fragile X
syndrome and fragile X tremor ataxia syndrome
[116,117]. Alzheimer’s disease is associated with
dysregulated expression of two other lncRNAs,
BC200 and BACE1-AS, which have been shown
future science group
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to regulate protein translation at postsynaptic
dendritic microdomains [118] and expression of
the amyloid-cleaving b-secretase, BACE1 [119],
respectively. A recent study using next-gen RNAsequencing analyses to exhaustively identify all
transcripts whose expression levels were changed
upon differentiation of induced pluripotent stem
cells into neurons revealed over 1200 transcripts
(out of a total of 5953) encoding lncRNAs and
pseudogenes, a number of which were mapped
to SNPs previously identified by GWA studies
as being associated with schizophrenia, bipolar
disorder or ASD [120]. The results of this study,
in combination with that of Kerin et al. [109]
and our previous findings from sequential
quantitative trait and case–control association
analyses of published GWA data that showed
that 18 novel SNPs in noncoding regions were
strongly associated with four subphenotypes of
ASDs [26], suggest that many more noncoding
elements will be found to play a significant role
in the pathobiology, if not etiology, of complex
neurological and psychiatric disorders.
Future directions in ASD research
& therapy

The preceding sections of this article illustrate
the enormous genomic complexity of ASDs
and emphasize the need to not only study,
but also integrate, whenever possible, findings
obtained at different levels of analyses, including
genetics, epigenetics, gene expression and
G × E interactions. While much of the research
effort on ASDs over the past 15 or more years
has been focused on identifying structural
genetic variants in protein-coding genes, which
have indeed provided valuable insight into
the neuropathology of ASDs (e.g., deficits in
synapse formation and axon guidance, among
others), it is becoming increasingly clear
that noncoding elements of the genome and
epigenetic mechanisms of gene regulation also
merit intensive research.
The need to incorporate subphenotypes
into autism research

As we move forward into the next phase of
autism research, which will undoubtedly take
advantage of the enormous capabilities of nextgen sequencing that, in turn, will produce
massive amounts of genomic data, we must keep
in mind the need to reduce the heterogeneity of
the ASD population under study by subgrouping
individuals according to clinical phenotypes,
specific traits or even comorbidities, which has
been demonstrated to improve LOD scores in
future science group
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genome-wide linkage analyses [9–14]. We have
also shown that reducing heterogeneity among
cases by subgrouping individuals with ASDs
according to severity of symptoms assessed by
the ADI-R [25] resulted in the identification
of subtype-specific differentially expressed
genes and associated SNPs from genomewide gene expression [24] and GWA analyses
[26], respectively. Among the differentially
expressed genes unique to one of the subtypes
of ASD (characterized by severe language
impairment), we observed 15 genes involved in
circadian rhythm, two of which immediately
suggest therapeutic options for this subgroup.
For example, a deficiency in AANAT, which is
the rate-limiting enzyme in the biosynthesis of
melatonin, suggests that melatonin supplements
may help to correct sleep disturbances exhibited
by many on the autism spectrum, as well as
alleviate some of the ASD symptoms that may
be related to circadian disruption. On the other
hand, a deficiency in DPYD, which predisposes
individuals to epilepsy, mental retardation
and ASD [121], may indicate anticonvulsant
medications as a first choice of pharmacologic
therapy for individuals with this subtype of
ASD. Thus, it is expected that the identification
of subtype-specific genes/pathways and SNPs
will promote the development and use of novel
pharmacologic interventions targeted toward
the specific biological deficits associated with a
given subphenotype of ASD as well as allow a
more specific, pharmacogenomically informative
diagnosis of ASDs.
Is a paradigm shift toward a systems
view of ASDs needed?

While ASDs are def ined primarily as
neu rode velopment a l d isorders, ma ny
individuals with an ASD manifest problems in
peripheral organ systems, such as the immune
system and gastrointestinal disorders. Indeed,
the plethora and varied functions of genes
shown to be dysregulated in gene expression
studies (such as circadian rhythm genes and
those involved in cytoskeletal arrangements,
muscle function and inflammation) as well
as those implicated by genetic studies suggest
that ASDs may be more accurately considered
a systems disorder with severe neurological and
behavioral manifestations. This paradigm shift
away from a purely neurocentric perspective to
a systems view of ASD would result in two
important implications for autism research and
therapy: first, peripheral tissues, such as bloodderived cells, may reflect at least some of the
www.futuremedicine.com
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molecular and pathway alterations contributing
to the ASD phenotype (as shown for the
reduction of RORA in both blood-derived and
brain tissues [24,44,45,47]), and thus be useful
surrogate experimental models for investigating
the molecular underpinnings of ASDs; second,
therapeutics aimed at resolving some of the
metabolic or systemic problems exhibited by
individuals with ASDs (e.g., gastrointestinal
problems and sleep disturbances) may also
prove to be beneficial in ameliorating some of
the ASD symptoms. The key to appropriate
systems-based therapeutics would come from
identifying the specific metabolic/biological
deficits affecting a particular individual or
subtype of ASD.
The promise of ncRNA in therapeutics
of ASDs

As discussed in a preceding section, ncRNAs
are involved in many gene regulatory functions,

and altered expression of a gene by ncRNA
can have long-lasting effects due to epigenetic
modifications, including DNA methylation,
which may be transmitted transgenerationally.
Thus, while it would be difficult to alter
the sequence of a protein-coding gene that
exhibits a genetic mutation or polymorphism
or to introduce a new functional gene by gene
therapy methods, it would be much more
feasible to regulate expression of a gene that
may be deficient or overexpressed in a disorder
using ncRNAs that can be targeted to a specific
gene by means of sequence complementarity.
However, the problem of delivery of ncRNAs
to the proper tissues is a major obstacle that
would need to be resolved. Although research
in the field of ncRNA, especially lncRNA, is
still in its infancy, the rapidly evolving next-gen
RNA sequencing technologies, which will allow
complete identification of all transcripts in both
healthy and diseased tissues, promise to yield

Executive summary
Introduction: why study genetics of autism?
Autism spectrum disorders (ASDs) are among the most heritable of psychiatric disorders.
However, no single gene can account for more than 1% of the cases of idiopathic autism, and the number of candidate genes
associated with ASDs is rapidly rising to >400.
One of the confounding factors in identifying causal variants in DNA is the clinical and phenotypic heterogeneity of ASDs, which
undoubtedly reflects multiple etiologies.
Beyond genetics: the need to consider epigenetics & environment
Discordance of autism diagnosis and phenotype among some sets of monozygotic twins suggests the contribution of epigenetic and
environmental factors to autism risk.
Epigenetic changes, including differences in DNA methylation, histone modification and microRNA expression, have been associated
with ASDs.
Environmental factors can affect risk for ASDs through direct, indirect and epigenetic mechanisms.
Epigenetic modifications may be transmitted transgenerationally, thus contributing a nongenetic but heritable component to autism
risk.
There is crosstalk between genetic and epigenetic mechanisms.
The need to explore ‘dark matter’ (noncoding) RNA in the etiology of ASDs
Much of DNA is transcribed, thus resulting in a large number of ncRNA transcripts, many of unknown functions.
Long ncRNAs (exceeding 200 base pairs) have been identified in both genetic and gene expression studies of ASDs.
Although gene regulatory functions are the suspected mechanisms for the effect of long ncRNAs, more research is needed to
understand their roles in the etiology and pathogenesis of ASDs.
Future directions in ASD research & therapy
While much of the recent focus of autism research has been on the search for structural variants in the protein-coding regions of genes
(i.e., the ‘trees’), the spotlight needs to be expanded to encompass gene-regulatory mechanisms (the ‘forest’), which include
transcribed regions outside of the reading frame in genes (e.g., introns), noncoding regulatory regions outside of the transcribed
regions of genes (e.g., enhancers), epigenetic modifications and ncRNAs, which are all capable of inducing pervasive dysregulation of
gene expression.
Although next-generation sequencing of whole genomes will undoubtedly provide massive amounts of data on both coding and
noncoding transcripts in healthy and diseased tissues, it will be necessary to study defined clinical/behavioral subphenotypes of ASDs in
order to elicit biologically meaningful information from such large-scale genomic studies.
A paradigm shift from a purely neurocentric view of ASDs to a ‘systems’ perspective will allow a more comprehensive unbiased
identification of biological deficits in specific subphenotypes of ASDs, which may be revealed through studies using peripheral tissues.
The identification of subtype-specific biological deficits is expected to reveal novel therapeutic targets as well as facilitate the
development of more personalized pharmacogenomics approaches to treatment of ASDs.
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true gems as we venture deeper into the ‘forest’
of dark matter RNA.
In exploring the genomic landscape of ASDs, it is
clear that we need to broaden our perspective of
the etiology of autism from the prevailing view
that focuses on the proximal ‘trees’ (i.e., exonic,
copy number and rare variants in protein-coding
genes) to examine the more expansive genomic
‘forest’ encompassing extensive gene-regulatory
elements, including epigenetic modifications and
ncRNAs, which, in turn, are both influenced
by environment. Beyond the question of
etiology, the more pressing issue for individuals
with an ASD, as well as for clinicians, is that
of effective and personalized therapies that
are targeted toward specific biological deficits
[49]. Identification of such deficits may benefit
from adopting a ‘systems’ perspective of ASDs
for which novel therapeutic strategies may be
revealed through studies of more easily accessible
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